Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06527300 | A Multicenter, Open-label, Single-arm, Phase II Study of NHWD-870 HCl in Adults and Adolescents with Advanced NUT Cancer | unknown | Phase 2 | 48 | Zhejiang Wenda Pharma Technology LTD.INDUSTRY | 1 | Jan 24, 2025 | clinicaltrials |
| NCT06410703 | CAN1012 Combined With PD-1 in Patients With Solid Tumors | unknown | Phase 1 / Phase 2 | 71 | Canwell Biotech LimitedINDUSTRY | 1 | Oct 31, 2024 | clinicaltrials |
| NCT06322095 | A Study of GH21 Combined With Previous Target Therapy or Immunotherapy in Patients With Advanced Solid Tumors | unknown | Phase 2 | 72 | Suzhou Genhouse Bio Co., Ltd.OTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06413615 | A Study of FDA022-BB05 in Advanced/Metastatic Solid Tumors | unknown | Phase 2 | 150 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2024 | clinicaltrials |
| NCT06224387 | CTS2190 Phase I /II Clinical Study in Patients | unknown | Phase 1 / Phase 2 | 224 | CytosinLab Therapeutics Co., Ltd.INDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT04185831 | A MolEcularly Guided Anti-Cancer Drug Off-Label Trial(MEGALiT) | unknown | Phase 2 | 167 | Uppsala University HospitalOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT03658785 | Immunotherapy for the Treatment of Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 40 | Tongji HospitalOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT04282031 | A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer | unknown | Phase 1 / Phase 2 | 224 | Beta Pharma (Suzhou) Co., Ltd.INDUSTRY | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06519110 | Neratinib Tablets Monotherapy for Advanced Solid Tumors With HER2 Mutations(CVL009-C2001) | unknown | Phase 2 | 60 | Convalife (Shanghai) Co., Ltd.INDUSTRY | 0 | Jul 25, 2024 | clinicaltrials |
| NCT05880043 | GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignancies | unknown | Phase 1 / Phase 2 | 50 | GI Cell, Inc.INDUSTRY | 1 | Jul 9, 2024 | clinicaltrials |
| NCT06490068 | Study of LTC004 Combine With Toripalimab in Patient With Solid Tumors Resistant to Immunotherapy | unknown | Phase 2 | 10 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT06439589 | Phase Ib/II Study of HRS2398 in Combination With Adebrelimab in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 88 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 5, 2024 | clinicaltrials |
| NCT03694249 | Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence | unknown | Phase 2 | 30 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT06233292 | A Study of ZG005 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 484 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jun 14, 2024 | clinicaltrials |
| NCT06239298 | A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 130 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jun 14, 2024 | clinicaltrials |
| NCT06136065 | 68 Gallium-Fibroblast Activating Protein Inhibitors-46 Positron Emission Tomography - Computerized Tomography for Molecular Assessment of Fibroblast Activation and Risk Assessment in Solid Tumors(FAPI) | unknown | Phase 2 | 100 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT04092673 | Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies(Zotatifin) | unknown | Phase 1 / Phase 2 | 30 | Effector TherapeuticsINDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT05804526 | A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours | unknown | Phase 1 / Phase 2 | 82 | RemeGen Co., Ltd.INDUSTRY | 1 | Apr 30, 2024 | clinicaltrials |
| NCT05865925 | Safety, Tolerability, Pharmacokinetics (PK), and Primary Clinical Efficacy of LY01616 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 78 | Luye Pharma Group Ltd.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT02266745 | A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts | unknown | Phase 2 | 109 | Promontory Therapeutics Inc.INDUSTRY | 2 | Apr 5, 2024 | clinicaltrials |
| NCT04903873 | A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 110 | EutilexINDUSTRY | 2 | Mar 15, 2024 | clinicaltrials |
| NCT06237413 | A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours | unknown | Phase 1 / Phase 2 | 110 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Mar 6, 2024 | clinicaltrials |
| NCT04780217 | Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 42 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Mar 4, 2024 | clinicaltrials |
| NCT04934514 | Clinical Study of IAH0968 in Patients With HER2-positive Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 97 | SUNHO(China)BioPharmaceutical CO., Ltd.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT04984668 | A Phase Ib/II Study of GT90001 Combined With KN046 in Solid Tumors | unknown | Phase 1 / Phase 2 | 216 | Suzhou Kintor Pharmaceutical Inc,INDUSTRY | 1 | Feb 9, 2024 | clinicaltrials |
| NCT05358379 | A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma | unknown | Phase 1 / Phase 2 | 330 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 3 | Feb 7, 2024 | clinicaltrials |
| NCT04983810 | A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma | unknown | Phase 1 / Phase 2 | 330 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 3 | Jan 25, 2024 | clinicaltrials |
| NCT06223308 | A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 54 | Shanghai Huaota Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 25, 2024 | clinicaltrials |
| NCT05576961 | Safety and Efficacy of RX-af01 Combined With PD-1 Antibody | unknown | Phase 1 / Phase 2 | 60 | Sun Yat-sen UniversityOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT05955157 | Combined S-1 With DC+CIK As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma | unknown | Phase 2 / Phase 3 | 52 | University of MalayaOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT04407741 | Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas | unknown | Phase 1 / Phase 2 | 100 | Chinese PLA General HospitalOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT05094804 | A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents | unknown | Phase 1 / Phase 2 | 172 | OncoResponse, Inc.INDUSTRY | 1 | Nov 2, 2023 | clinicaltrials |
| NCT06056323 | A Study of HB0045 Injection in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 71 | Shanghai Huaota Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 23, 2023 | clinicaltrials |
| NCT06092268 | A Phase IB/II Clinical Study of SHR-A2009 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 270 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 0 | Oct 23, 2023 | clinicaltrials |
| NCT06082557 | A Study to Observe and Evaluate the Safety and Efficacy of T60c Injection for Treatment of Advanced Solid Tumor Patients | unknown | Phase 1 / Phase 2 | 62 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Oct 13, 2023 | clinicaltrials |
| NCT06082570 | A Study to Observe and Evaluate the Safety and Efficacy of c610 Injection for Treatment of Advanced Solid Tumor Patients | unknown | Phase 1 / Phase 2 | 62 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Oct 13, 2023 | clinicaltrials |
| NCT06078670 | PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 96 | Fujian Cancer HospitalOTHER_GOV | 0 | Oct 12, 2023 | clinicaltrials |
| NCT04717674 | [18F]FPIA PET/CT Imaging in Patients With Solid Tumours([18F]FPIA) | unknown | Phase 2 | 21 | University College, LondonOTHER | 1 | Oct 3, 2023 | clinicaltrials |
| NCT03382340 | IMX-110 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 70 | Immix Biopharma Australia Pty LtdINDUSTRY | 2 | Sep 28, 2023 | clinicaltrials |
| NCT06047860 | A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer | unknown | Phase 2 | 30 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06041035 | A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 115 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 18, 2023 | clinicaltrials |
| NCT06008366 | A Phase 1/2 Study of 7MW3711 in Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 281 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Sep 13, 2023 | clinicaltrials |
| NCT06008379 | A Study of 7MW3711 in Subjects With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 164 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Sep 13, 2023 | clinicaltrials |
| NCT06022289 | Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors | unknown | Phase 2 | 20 | Tianjin Medical University Second HospitalOTHER | 1 | Sep 1, 2023 | clinicaltrials |
| NCT05986981 | MUC1 Therapeutic Tumor Vaccine in Advanced Solid Cancers | unknown | Phase 2 | 20 | Peking Union Medical College HospitalOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT05840835 | Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors(IMMINENT-01) | unknown | Phase 1 / Phase 2 | 60 | Immix Biopharma, Inc.INDUSTRY | 1 | Aug 8, 2023 | clinicaltrials |
| NCT04250948 | Efficacy of Perioperative Chemotherapy Plus PD-1 Antibody in the Locally Advanced Gastric Cancer | unknown | Phase 2 | 108 | Sun Yat-sen UniversityOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05396339 | A Clinical Trial to Evaluate the Effect of IAE0972 in Patients With Advanced Malignant Solid Tumors. | unknown | Phase 1 / Phase 2 | 120 | SUNHO(China)BioPharmaceutical CO., Ltd.INDUSTRY | 1 | Jul 19, 2023 | clinicaltrials |
| NCT05173805 | Phase I Clinical Study of YL-15293 in Patients With Advanced Solid Tumor With KRAS Mutation | unknown | Phase 1 / Phase 2 | 150 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 1 | Jul 18, 2023 | clinicaltrials |
| NCT05944185 | Phase I/II Study of αPD1-MSLN-CAR T Cells in MSLN-positive Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 42 | Shanghai Cell Therapy Group Co.,LtdINDUSTRY | 1 | Jul 14, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Jan 24, 2025source: clinicaltrials